Morfin Epidural (Morphine Hydrochloride)

Morphine hydrochloride acts as an agonist at μ‑opioid receptors located in the dorsal horn of the spinal cord. By binding these receptors, it inhibits the release of excitatory neurotransmitters such as substance P and glutamate, thereby decreasing nociceptive signal transmission and producing analgesia at the spinal level.

The appropriate dose of Morfin Epidural is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and individual risk factors. Healthcare professionals calculate the dose according to established guidelines and adjust it according to therapeutic response and safety monitoring.

Safety data for epidural morphine in pregnancy are limited, and the drug should only be used when the potential benefit justifies any possible risk to the fetus. Because morphine can pass into breast milk, caution is advised for breastfeeding mothers, and alternative analgesic strategies should be considered whenever possible.

To request Morfin Epidural, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with alternatives such as fentanyl or hydromorphone, morphine has a slower onset but a longer duration of action when administered epidurally, which can be advantageous for prolonged postoperative pain control. Its potency is lower, requiring higher milligram doses, and it carries a higher risk of delayed respiratory depression, necessitating vigilant monitoring.

Morfin Epidural should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from direct light and moisture, and avoid freezing. Follow standard aseptic techniques when preparing the solution for epidural injection.

The medication is supplied as a sterile solution for injection and is administered by a qualified healthcare professional using an epidural catheter placed in the epidural space of the spine. The dose is injected slowly, and the patient is observed for analgesic effect and potential adverse reactions.

The most critical safety concerns include severe respiratory depression, which may be delayed for several hours after administration, and rare but life‑threatening reactions such as anaphylaxis or meningitis from contamination. Continuous respiratory monitoring and adherence to aseptic technique are essential to mitigate these risks.

Morfin Epidural is contraindicated in patients with known hypersensitivity to morphine or any component of the formulation, those with uncontrolled severe respiratory disease, and individuals who have received intrathecal or epidural opioids within the preceding 24 hours. Caution is also advised in patients with significant renal or hepatic impairment.